Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs). (INFECT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01790698 |
Recruitment Status :
Completed
First Posted : February 13, 2013
Last Update Posted : April 23, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Soft Tissue Infections Necrotizing Fasciitis Necrotizing Soft Tissue Infections |
Patients will be prospectively recruited at 5 clinical centers (Rigshospitalet, Karolinska University Hospital, Blekinge University, Sahlgrenska University and University of Bergen). Clinical definition criteria for NSTI: NSTI is a clinical diagnosis. Initial signs are the occurrence of erythema, pain or tenderness beyond margins of erythema and swelling. Imaging and laboratory tests have little predictive value in the early stage. The gold standard modality for diagnosis of NSTI remains operative exploration. Operative findings that are consistent with NSTI include "dishwater or foul smelling discharge, necrosis or lack of bleeding and loss of the normal resistance of the fascia to finger dissection. A patient admitted for critical care and / or surgery due to severe soft tissue infection of the fascia, muscle or subcutaneous tissues will be enrolled in this NSTI study. The patients will be stratified based on several clinical parameters including among others SAPS score, presence of multiorgan failure, and hypotensive shock. This stratification serves to classify the patients in defined severity classes to be used in analyses and modeling. Detailed demographic and clinical information will be documented in the interactive database including: age, gender, medical history, clinical presentation (shock, multiorgan failure etc), treatment and outcome. Disease progress: The clinical database is to contain information on the spread of the infection at the different times of inspection/surgical intervention. Severity of the infections will be documented by use of the updated CREST classification scheme, SAPS III score, and the LRINEC score. Detailed information regarding antimicrobial therapy, surgical intervention, innovative therapy (IVIG and HBO) will be documented.
Samples will be collected from all enrolled patients. Standard operating procedures will be generated and implemented at all sites to ensure a quality assured collection and handling of samples. Samples to be collected include (a) isolates, (b) blood samples to be processed for DNA, RNA and plasma/cells and (c) tissue biopsies in all patients whenever surgical interventions are indicated. The samples will be analyzed using genomics, transcriptomics, metabolomics and proteomics.
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 409 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 3 Months |
Official Title: | Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures That Dictate Severity of Tissue Infection |
Study Start Date : | January 2013 |
Actual Primary Completion Date : | June 2017 |
Actual Study Completion Date : | January 2018 |

- Prognostic/diagnostic value (ROC curves: specificity, sensitivity, predictive values) of classification and severity scores in NSTIs [ Time Frame: 3 months - further oservation up to 24 month may apply ]
- Effect of IVIG and HBO-therapy on mortality rates in matched (defined by severity scores and aetiology) NSTI patients [ Time Frame: 3 months - further observation up to 24 month may apply ]
- Presence of hypotension, multiorgan failure, or fatal outcome of NSTI in relation to microbiologic aetiology [ Time Frame: 3 months - further observation up to 60 month may apply ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
Necrotizing soft tissue infections
Exclusion Criteria:
Patients under the age of 18 years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01790698
Denmark | |
Rigshospitalet | |
Copenhagen, Denmark, 2100 | |
Norway | |
University of Bergen | |
Bergen, Norway, 5021 | |
Sweden | |
Sahlgrenska University Hospital | |
Gothenburg, Sweden, SE-416 50 | |
Blekinge Hospital | |
Karlskrona, Sweden, SE-371 85 | |
Karolinska University Hospital | |
Stockholm, Sweden, SE-171 76 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Anna Norrby-Teglund, Professor, Coordinator of INFECT, Karolinska Institutet |
ClinicalTrials.gov Identifier: | NCT01790698 |
Other Study ID Numbers: |
INFECT-FP7305340 |
First Posted: | February 13, 2013 Key Record Dates |
Last Update Posted: | April 23, 2018 |
Last Verified: | April 2018 |
Necrotizing fasciitis Streptococcus pyogenes Staphylococcus aureus Immunopathogenesis |
Infections Communicable Diseases Soft Tissue Infections Fasciitis |
Fasciitis, Necrotizing Disease Attributes Pathologic Processes Musculoskeletal Diseases |